Rob Califf returns to lead the FDA as the U.S. continues to cope with the pandemic and opioid epidemic. The agency also is facing questions about its processes for accelerated drug approvals.
Read full article here
About the Author
Rob Califf returns to lead the FDA as the U.S. continues to cope with the pandemic and opioid epidemic. The agency also is facing questions about its processes for accelerated drug approvals.
Read full article here
